Sarepta Therapeutics
30-Second Executive Brief
Executive Assessment
Sarepta Therapeutics functions as a regional institution within Healthcare & Life Sciences, backed by 0% sourcing coverage, with accelerating strategic relevance.
- Maintains 1 mapped relationship across the graph
- 0% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 0%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 1
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
US biotechnology company specializing in gene therapies for Duchenne muscular dystrophy and rare diseases; reported Q2 2026 total revenue of $401 million (down 34% year-over-year) as ELEVIDYS gene therapy volumes declined sharply following 2025 safety events and a narrowed product label; narrowed full-year 2026 net product revenue guidance to $1.2-1.3 billion.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions AbbVie, Amgen
“Dr. Severino brings more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck”
SEC 8-K exhibit (0001193125-26-335056) · Aug 5, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Business Wire — Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developmentscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Sarepta Therapeutics — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Sarepta Therapeutics's Timeline
A sourced, dated history of Sarepta Therapeutics's key moments — founding to present.
Aug 2026 · Q2 2026 revenue falls 34% as ELEVIDYS demand drops after safety events
Sarepta Therapeutics reported Q2 2026 total revenue of $401 million, down 34% year-over-year, with ELEVIDYS net product revenue of $98.1 million reflecting a sharp volume decline following 2025 safety events and a narrowed label; the company narrowed its full-year 2026 net product revenue guidance to $1.2-1.3 billion.